A five-year-old class action against BHP over the collapse of a Brazilian dam is seeking to amend the group definition following a judgment limiting the class size, but the mining company says it should not be punished for the applicant’s pleading mistake.
Westpac subsidiary BT Funds Management and Tal Life Insurance have foreshadowed applications to strike out the pleadings of a class action alleging superannuation customers were overcharged for insurance coverage.
A judge has dismissed the corporate regulator’s first-ever case over unfair insurance contracts terms, finding it was not unfair for an insurer to require customers to notify it if anything changed about their home or its contents.
Ashurst has bolstered its disputes team by reclaiming a senior commercial litigation partner from Clifford Chance, who has predicted more defence firms will cross over and represent plaintiffs in class actions.
Indian generics company Sun Pharma has taken Otsuka Pharmaceutical to court, alleging an extension for the patent for an injectable form of the Japanese drug maker’s blockbuster antipsychotic Abilify was wrongly granted and should be invalidated.
A judge has set aside subpoenas in a class action against Mercedes-Benz over alleged emissions cheating seeking material to identify group members and clarify the composition of the class, finding they were not issued for a legitimate forensic purpose.
A client of EY has sued a former partner at the firm, accusing them of collecting $700,000 in secret payments as part of a tax loss scheme.
A judge has rejected sweeping suppression orders sought by the founders of vitamin giant Nature’s Care over documents in a $200 million tax debt stoush with the Deputy Commissioner of Taxation, instead making limited suppression orders in light of the “serious” allegations made in the case.
Aussie Broadband is seeking to set aside a notice from the board of internet service provider Superloop directing it to sell down its 19.9 shareholding in the company, arguing the sell order was made for an improper purpose amid a “contested takeover battle” between the companies.
A judge has ordered Western Australian biotech Holista Colltech to pay a penalty of $1.8 million for making misleading representations to the market about sales of its natural sanitiser product during the height of the COVID-19 pandemic, and hit its CEO with a four-year ban.